Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.29 EPS (ttm)4.10 Insider Own0.04% Shs Outstand2.85B Perf Week0.48%
Market Cap167.00B Forward P/E15.28 EPS next Y3.84 Insider Trans-22.63% Shs Float2.85B Perf Month-5.65%
Income11.92B PEG3.01 EPS next Q0.76 Inst Own75.00% Short Float0.80% Perf Quarter-1.21%
Sales42.24B P/S3.95 EPS this Y176.90% Inst Trans-0.46% Short Ratio2.11 Perf Half Y-0.91%
Book/sh15.70 P/B3.73 EPS next Y12.93% ROA11.50% Target Price63.85 Perf Year5.93%
Cash/sh5.03 P/C11.64 EPS next 5Y4.74% ROE24.70% 52W Range52.10 - 63.62 Perf YTD3.15%
Dividend1.80 P/FCF- EPS past 5Y-6.30% ROI0.40% 52W High-7.92% Beta0.32
Dividend %3.07% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin63.50% 52W Low12.44% ATR0.86
Employees76000 Current Ratio1.30 Sales Q/Q-7.40% Oper. Margin21.50% RSI (14)46.39 Volatility1.06% 1.42%
OptionableYes Debt/Eq0.62 EPS Q/Q876.90% Profit Margin28.20% Rel Volume0.90 Prev Close58.54
ShortableYes LT Debt/Eq0.41 EarningsFeb 04 BMO Payout42.70% Avg Volume10.74M Price58.58
Recom2.50 SMA20-0.69% SMA50-2.03% SMA2000.57% Volume9,663,600 Change0.07%
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
Jan-24-11Reiterated Deutsche Bank Buy $48 → $43
Jan-24-11Reiterated Barclays Capital Overweight $43 → $41
Mar-02-15 03:45PM  Backed by Genentech alum Dave Goeddel, this company looks like the next biotech IPO at bizjournals.com
08:00AM  Merck to Present at the 35th Annual Cowen Health Care Conference Business Wire
Feb-27-15 05:43PM  Your first trade for Monday, March 2 at CNBC
05:28PM  Fast Money Final Trade: FEZ, MU, MRK & GMCR CNBC
04:15PM  Interested In Pharmaceutical Stocks? Try Novartis (ADR) at Investopedia
04:14PM  Dow 30 Stock Roundup: Home Depot Beats, Chevron Issues $6B in Bonds - Analyst Blog Zacks
02:09PM  MERCK & CO., INC. Files SEC form 10-K, Annual Report EDGAR Online
12:24PM  Kahn Brothers Top Picks to Close 2014, as Founder Irving Kahn Passes at 109 at Insider Monkey
10:09AM  Bayer Q4 Net Income Down Y/Y, Provides 2015 Outlook - Analyst Blog Zacks
08:04AM  Why should you invest in healthcare ETFs? Market Realist
06:43AM  Decision on Ebola mass vaccination in August at earliest - WHO Reuters
05:42AM  Decision on widespread Ebola vaccination in August at earliest - WHO Reuters
Feb-26-15 03:18PM  Mercks 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDCs Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21 Business Wire
Feb-25-15 05:23PM  Spark Therapeutics stock soars CNBC
03:34PM  Heavy News Day For Several Biotech Stocks Benzinga
11:00AM  Eight Undervalued Key Antibiotics Players at Barrons.com
10:38AM  Gilead & AbbVie: It Doesn't Matter Which Drug is Better, Just Who Will Pay at Barrons.com
08:00AM  New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions Business Wire
Feb-24-15 06:05PM  Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog Zacks
05:06PM  Big pharma diversifies business to mitigate patent risk Market Realist
02:15PM  Merck takes equity, links up with diabetes drug developer NGM at American City Business Journals
12:51PM  Merck Announces Second-Quarter 2015 Dividend Business Wire
10:40AM  [video]Merck & Company Grants Free License for Pediatric HIV Drug at TheStreet
06:52AM  Merck grants free license for pediatric HIV drug AP
03:00AM  Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries Business Wire
Feb-23-15 06:26PM  Agilent-ONO Companion Diagnostics Aim - Analyst Blog Zacks
06:22PM  Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due Business Wire
05:15PM  Biotech battles 'Superbug' CNBC
11:08AM  Merck to team With NGM to develop diabetes and obesity treatments at MarketWatch
10:47AM  Mercks Research Man Saved Biotech Deal With Juicy Pitch at Bloomberg
08:25AM  Merck to Team With NGM to Develop Diabetes, Obesity Treatments at The Wall Street Journal
07:00AM  NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics Business Wire
07:00AM  Merck Bets $450M On 'Old School' Biotech From NGM at Forbes
Feb-20-15 02:40PM  Eli Lilly Extends Phase III Cholesterol Study by Six Months - Analyst Blog Zacks
12:30PM  What's in Store for Endocyte (ECYT) this Earnings Season? - Analyst Blog Zacks
12:28PM  What it takes to be called big pharma Market Realist
10:34AM  Former Merck Analyst Pleads Guilty to Insider Trading Charges at The Wall Street Journal
Feb-19-15 08:27PM  Ex-financial analyst pleads guilty in insider trading case AP
07:33PM  Ex-Merck Analyst Zwerko Pleads Guilty to Insider-Trading at Bloomberg
07:05PM  Superbug Spread Reveals Thin Pipeline of Newest Antibiotics at Bloomberg
05:27PM  Who can beat the 'superbug'? CNBC
04:55PM  Ex-Merck analyst pleads guilty to U.S. insider trading charges Reuters
08:30AM  NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate GlobeNewswire
05:58AM  Candidate to lead FDA has close ties to big pharma at Fortune
Feb-18-15 10:59AM  Why Big Pharma Must Cure Its Bad Rap at Forbes
Feb-17-15 05:17PM  Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Zacks
Feb-13-15 05:11AM  Mercer International posts 4Q profit AP
Feb-12-15 04:10PM  Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog Zacks
Feb-10-15 05:31PM  MERCK & CO., INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
03:43PM  Canadian government to require drug shortage notice Reuters
11:19AM  Venezuela says new forex platform will be "totally free" Reuters
09:26AM  Venezuela to announce new forex system; devaluation expected Reuters
Feb-09-15 04:59PM  Microsoft Does Largest Corporate Debt Sale Of Year at Investor's Business Daily
12:50PM  Ex-Merck analyst facing insider trading charges to plead guilty -lawyer Reuters
Feb-06-15 02:15PM  Dow 30 Stock Roundup: Disney, Exxon Beat, United Technologies Raises Dividend - Analyst Blog Zacks
06:05AM  Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx at TheStreet
Feb-05-15 07:37PM  Merck Prices $8.0 Billion Debt Offering Business Wire
03:01PM  Low rates, M&A spur flood of pharma debt deals Reuters
02:04PM  Final Trades Feb. 5, 2015 at CNBC
12:58PM  FMHR Final Trade: H&R Block, Merck & Hertz CNBC
12:09PM  Merck & Co., Inc. -- Moody's assigns A2 rating to Merck & Co.'s new unsecured notes at Moody's
11:00AM  Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary Zacks
10:12AM  Stocks trade higher; Dow jumps 100 points on Pfizer at CNBC
10:10AM  Company News for February 05, 2015 - Corporate Summary Zacks
12:09AM  [$$] Merck Sales Fall on Stronger Dollar, Patent Expirations at The Wall Street Journal
Feb-04-15 06:41PM  Gilead's deep discounts fuel investor worries about drug pricing Reuters
03:47PM  Gilead Sciences: Look on the Bright Side? at Barrons.com
03:13PM  FDA rescinds breakthrough status for Mercks hepatitis C drug at Fortune
02:25PM  Merck Sales Fall on Stronger Dollar, Patent Expirations at The Wall Street Journal
02:10PM  Merck says hepatitis C treatment to lose "breakthrough" status Reuters
01:29PM  Merck defends children's vaccines after measles outbreak at Financial Times
01:05PM  US STOCKS-S&P, Nasdaq down after 2-day run up; biotechs, energy fall Reuters
12:39PM  Merck (MRK) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
12:27PM  4 Stocks, 4 trades: Merck, Kohl's & more CNBC
12:05PM  Merck: Dollar, Hepatitis-C Do the Damage at Barrons.com
11:26AM  Drugmaker Merck posts spike in 4Q profit, beats forecasts AP
11:21AM  Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog Zacks
11:10AM  US STOCKS-Wall St dips after 2-day run as energy rally stalls Reuters
10:10AM  Wed., Feb. 4: Watch GM on Strong Earnings at MarketWatch
10:04AM  Staples Finalizes Office Depot Deal at MarketWatch
09:49AM  US STOCKS-Wall St down after 2-day run after ADP as energy drags Reuters
09:41AM  Merck's Disappointing Forecast Means Investors Should Avoid This Stock at TheStreet
09:41AM  [video]Merck's Disappointing Forecast Means Investors Should Avoid This Stock at TheStreet
09:40AM  Loss of Hep C Drug Status Weighs on Merck Earnings at 24/7 Wall St.
09:18AM  Merck Tops Estimates, But Warns Of Currency Headwinds at Forbes
08:48AM  Cramer: Don't believe naysayers CNBC
08:37AM  Merck (MRK) Tops on Q4 Earnings & Revenues - Tale of the Tape Zacks
08:23AM  Merck reports mixed results CNBC
08:07AM  FDA Rescinds Breakthrough Status for Mercks Hepatitis C Drug at Bloomberg
08:00AM  Merck & Co Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:27AM  Merck issues cautious 2015 forecast, citing dollar Reuters
07:25AM  Merck tops Street 4Q forecasts AP
07:20AM  Mercks 2015 Will Be Low Point as Sales Projected to Decrease at Bloomberg
07:14AM  MERCK & CO., INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
07:07AM  Q4 2014 Merck & Co Inc Earnings Release - Before Market Open CCBN
07:02AM  Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results Business Wire
Feb-03-15 05:16PM  Bill would require HPV vaccine for Nevada school enrollment AP
04:07PM  Merck Canada Inc. help raise awareness for World Cancer Day CNW Group
02:21PM  Stocks rally on oil; Dow, S&P up more than 1% at CNBC
02:05PM  Honeywells Performance Materials and Technologies segment Market Realist
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM